4.7 Review

An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena

期刊

PHARMACOLOGY & THERAPEUTICS
卷 183, 期 -, 页码 90-117

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2017.10.004

关键词

Metallothioneins; Cancer; Diagnosis; Therapy; Hypermethylation

资金

  1. Czech Agency for Healthcare Research, AZV [15-28334A]
  2. Ministry of Education, Youth and Sports of the Czech Republic [LQ1601]
  3. National Research, Development and Innovation Office - NKFIH [120206]
  4. MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203]
  5. [GINOP-2.3.2-15-2016-00005]

向作者/读者索取更多资源

Metallothioneins (MTs) belong to a group of small cysteine-rich proteins that are ubiquitous throughout all kingdoms. The main function of MTs is scavenging of free radicals and detoxification and homeostating of heavy metals. In humans, 16 genes localized on chromosome 16 have been identified to encode four MT isoforms labelled by numbers (MT-1-MT-4). MT-2, MT-3 and MT-4 proteins are encoded by a single gene. MT-1 comprises many (sub)isoforms. The known active MT-1 genes are MT-1A,-1B,-1E,-IF,-1G,-1H,-1M and -1X. The rest of the MT-1 genes (MT-1C,-1D,-11,-1J and -1L) are pseudogenes. The expression and localization of individual MT (sub)isoforms and pseudogenes vary at intra-cellular level and in individual tissues. Changes in MT expression are associated with the process of carcinogenesis of various types of human malignancies, or with a more aggressive phenotype and therapeutic resistance. Hence, MT (sub)isoform profiling status could be utilized for diagnostics and therapy of tumour diseases. This review aims on a comprehensive summary of methods for analysis of MTs at (sub)isoforms levels, their expression in single tumour diseases and strategies how this knowledge can be utilized in anticancer therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据